Nanobiotix SA is a France-based nanomedicine company. The Company designs and manufactures nanoparticles that safely enhance the efficacy of radiation therapy in the treatment of cancer. It develops new tools for cancer that utilize a physical mode of action at the cellular level of the cancer cell. The Company's NanoXray technology comprises three products. Local treatment (surgery and radiotherapy) provides potential cure and gives the systemic treatment a better chance to life expectancy. NanoXray products are developed for the efficacy of radiotherapy in the tumor cell. Nanobiotix is a spin-off of the State University of New York (SUNY) at Buffalo.
Biotechnology & Drugs
What the Analysts think about Nanobiotix
Majority rating from 5 analysts.
Average projection from 3 analysts.
Average price target
Nanobiotix Financial Performance
Income StatementBalance sheetCash Flow
0% profit margin
Revenues and expenses
Nanobiotix Earnings Performance
Earnings per share (EPS)
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Buy or sell Nanobiotix stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.